Biomarkers in prostate cancer epidemiology

Cancers

Volumn 3, Issue 4, 2011, Pages 3773-3798

  Verma, Mukesh ^a   Patel, Payal ^a   Verma, Mudit ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Biomarker; Cancer detection; Diagnosis; Epigenetics; Genetics; Prostate cancer; Treatment

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ACID PHOSPHATASE PROSTATE ISOENZYME; CALCIUM; CAVEOLIN 1; CHROMOGRANIN A; DISABLED HOMOLOG 2 INTERACTING PROTEIN; EARLY PROSTATE CANCER ANTIGEN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; HUMAN KALLIKREIN 2; KALLIKREIN; KATANIN P60; KI 67 ANTIGEN; MICRORNA; MICROTUBULE PROTEIN; POLYCOMB GROUP PROTEIN; PROSTATE ANTIGEN; PROSTATE PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE STEM CELL ANTIGEN; PROTEIN B7 H3; SELENIUM; TUMOR MARKER; UNCLASSIFIED DRUG; VITAMIN D;

ANDROGEN DEPRIVATION THERAPY; CALCIUM BLOOD LEVEL; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DIET SUPPLEMENTATION; EPIGENETICS; ERG GENE; EXOSOME; GENE; GENE FUSION; GENETIC MARKER; GENETIC TRANSCRIPTION; GOLPH2 GENE; GSTP 1 GENE; HEPSIN GENE; HUMAN; PCA3 GENE; PDLIM4 GENE; PIM1 GENE; PREVALENCE; PROSTATE CANCER; PROSTATECTOMY; PROTEOMICS; REVIEW; RISK ASSESSMENT; SMOKING CESSATION; TMPRSS2 GENE; VITAMIN BLOOD LEVEL;

EID: 84055184656     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3043773     Document Type: Review

References (111)

1. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics. CA Cancer J. Clin. 2010, 60, 277-300.
2. Jamel, A.; Center, M.M.; De Santis, C.; Ward, E.M. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol. Biomarkers Prev. 2010, 19, 1893-1907.
3. Chornokur, G.; Dalton, K.; Borysova, M.E.; Kumar, N.B. Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate 2011, 71, 985-997.
4. Parkin, D.M.; Bray, F. Global cancer statistics. CA Cancer J. Clin. 2005, 55, 74-108.
5. Berg, C.D. The prostate, lung, colorectal, and ovarian cancer screening trial: The prostate cancer screening results in context. Acta Oncol. 2011, 50, 12-17.
6. Tosoian, J.J.; Trock, B.J.; Landis, P.; Feng, Z.; Epstein, J.I.; Partin, A.W.; Walsh, P.C.; Carter, H.B. Active surveillance program for prostate cancer: An update of the Johns Hopkins experience. J. Clin. Oncol. 2011, 29, 2185-2190.
7. Sandblom, G.; Varenhorst, E.; Rosell, J.; Lofman, O.; Carlsson, P. Randomized prostate cancer screening trial: 20 year follow up. BMJ 2011, 342, 1-6.
8. Shigeta, K.; Naito, Y. Early prostate cancer - treat or watch. N. Engl. J. Med. 2011, 365, 568-569.
9. Jankovic, J.; Sipetic, S. The rising incidence and mortality of prostate cancer in Belgrade population. Coll. Antropol. 2011, 35, 499-503.
10. Zhang, L.; Yang, B.X. Prostate cancer: An emerging threat to the health of aging men in Asia. Asian J. Androl. 2011, 13, 574-578.
11. Ondrusova, M.; Muzik, J.; Kliment, J.; Gulis, G.; Ondrus, D. Prostate cancer incidence and mortality in selected countries of Central Europe. Klin. Onkol. 2011, 24, 126-132.
12. Bosetti, C.; Rodriguez, T. Trends in cancer mortality in Mexico, 1981-2007. Eur. J. Cancer Prev. 2011, 20, 355-363.
13. Jung, K.W.; Shin, H.R.; Kong, H.J.: Park, S.; Won, Y.J.; Choi, K.S.; Park, E.C. Long-term trends in cancer mortality in Korea (1983-2007): A joinpoint regression analysis. Asian Pac. J. Cancer 2010, 11, 1451-1457.
14. Tseng, C.H. Prostate cancer mortality in taiwanese men: Increasing age-standardized trend in general population and increased risk in diabetic men. Ann. Med. 2011, 43, 142-150.
15. Gibson, T.N.; Hanchard, B.; Waugh, N.; McNaughton, D. Thirty-year trend in incidence and agedistribution of prostate cancer in Kingston and St. Andrew, Jamaica. 1978-2007. West Indian Med. J. 2011, 60, 9-12.
16. Katrim-Kos, H.E.; Kiemeney, L.A. Progress against cancer in the Netherlands since the late 1980s: An epidemiological evaluation. Int. J. Caner 2011, doi:10.1002/ijc.26315.
17. Choi, M.; Craft, B.; Geraci, S.A. Surveillance and monitoring of adult cancer survivors. Am. J. Med. 2011, 124, 598-601.
18. Dai, Q.; Motley, S.S.; Smith, J.A.; Concepcion, R.; Barcosas, D.; Byerly, S.; Fowke, J.H. Blood magnesium, and the interaction with calcium, on the risk of high-grade prostate cancer. PLoS One 2011, 6, e18237.
19. Peng, X.; Guo, W.; Liu, T.; Wang, X.; Tu, X.; Xiong, D.; Chen, S.; Lai, Y.; Du, H.; Chen, G.;Liu, G.; Huang, S.; Zou, X. Identification of miRs-143 and -145 that Is Associated with Bone Metastasis of Prostate Cancer and Involved in the Regulation of EMT. PLoS One 2011, 6, e20341.
20. Haiman, C.A.; Chen, G.K.; Blot, W.J.; Strom, S.S.; Berndt, S.I.; Kittles, R.A.; Rybicki, B.A.; Isaacs, W.B.; Ingles, S.A.; Stanford, J.L.; et al. Characterizing Genetic Risk at Known Prostate Cancer Susceptibility Loci in African Americans. PLoS Genet. 2011, 7, e1001387.
21. Mordukhovich, I.; Reiter, P.L.; Backes, D.M.; Family, L.; McCullough, L.E.; O'Brien, K.M.; Razzaghi, H.; Olshan, A.F. A review of African American-white differences in risk factors for cancer: Prostate cancer. Cancer Causes Control 2011, 22, 341-357.
22. Schulz, W.A.; Hoffmann, M.J. Epigenetic mechanisms in the biology of prostate cancer. Semin. Cancer Biol. 2009, 19, 172-180.
23. Knudsen, B.S.; Vasioukhin, V. Mechanisms of prostate cancer initiation and progression. Adv. Cancer Res. 2010, 109, 1-50.
24. Brenner, J.C.; Atteq, B.; Li, Y.; Yocum, A.K.; Cao, Q.; Asangani, I.A.; Patel, S.; Wang, X.; Liang, H.; Yu, J.; Palanisamy, N.; et al. Mechanistic rationale for inhibition of popy (ADPribose) polymerase in ETS gene fusion positive prostate cancer. Cancer Cell 2011, 19, 664-678.
25. Tomlins, S.A.; Laxman, B.; Varambally, S.; Cao, X.; Yu, J.; Helgeson, B.E.; Cao, Q.; Presner, J.R.; Rubin, M.A.; Shah, R.B.; et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008, 10, 177-178.
26. Mosquera, J.M.; Mehra, R.; Regan, M.M.; Perner, S.; Genega, E.M.; Bueti, G.; Shah, R.B.; Gaston, S.; Tomlins, S.A.; Wei, J.T.; et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin. Cancer Res. 2009, 15, 4706-4711.
27. Narod, S.A.; Seth, A.; Nam, R. Fusion of the ETS gene family and prostate cancer. Br. J. Cancer 2008, 99, 847-851.
28. Brenner, J.C.; Chinnaiyan, A.M. Disruptive events in the life of prostate cancer. Cancer Cell 2011, 19, 301-303.
29. Yu, J.; Yu, J.; Mani, R.S.; Cao, Q.; Brenner, C.J.; Cao, X.; Wang, X.; Wu, L.; Li, J.; Hu, M.; Gong, Y.; et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusion in prostate cancer progression. Cancer Cell 2010, 17, 443-454.
30. Robbins, C.M.; Tembe, W.A.; Baker, A.; Sinari, S.; Moses, T.Y.; Beckstron Sternberg, S.; Beckstron-Sternberg, J.; Berrett, M.; Long, J.; Chinnaiyan, A.; Lowey, J.; et al. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res. 2011, 21, 47-55.
31. Friedenreich, C.M.; Nielson, H.K.; Lynch, B.M. State of the epidemiological evidence on physical activity and cancer prevention. Eur. J. Cancer 2010, 46, 4593-4604.
32. Lillini, R.; Vercelli, M.; Quaglia, A.; Micheli, A.; Capoccia, R. Use of socio-economic factors and healthcare resources to estimate cancer survival in European countries with partial national cancer registration. Tumori 2011, 97, 265-274.
33. Khan, N.; Afaq, F.; Mukhtar, H. Life style as risk factor for cancer: Evidence from human studies. Cancer Lett. 2010, 293, 133-143.
34. Hardin, J.; Cheng, I.; Witte, J.S. Impact of consumption of vegetable, fruit, grain and high glycemic index foods on aggressive prostate cancer risk. Nutr. Cancer 2011, 63, 860-872.
35. Novotny, L.; Rauko, P.; Kombian, S.B.; Edaflogho, I.O. Selinium as a chemopreventive anti-cancer agent: Reality or wishful thinking? Neoplasma 2010, 57, 383-391.
36. Bubley, G.J.; Carducci, M.C.; Dahut, W.; Dawson, N.; Daliani, D.; Eisenberger, M., Figg, W.D.; Friedin, B.; Halabi, S.; Hudes, G.; et al. Eligibility and response guidelines for phase II clinical trials in androgen independent prostate cancer: Recommendations from the Prostate Specific Antigen Working Group. J. Clin. Oncol. 1999, 17, 3461-3467.
37. Scher, H.I.; Halabi, S.; Tannock, I.; Morris, M.; Sternberg, C.N.; Carducci, M.A.; Higano, C.; Bubley, G.J; Driecer, R.; Petrylak, D.; et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Group. J. Clin. Oncol. 2008, 26, 1148-1159.
38. Venderbos, L.D.; Roobol, M.J. PSA-based prostate cancer screening: The role of active surveillance and informed and shared decision making. Asian J. Androl. 2011, 13, 219-224.
39. Sardana, G.; Dowell, B.; Diamandis, E.P. Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin. Chem. 2008, 54, 1951-1960.
40. Han, B.; Suelman, K. ETS gene aberrations in atypical cribriform lesions of the prostate: Implications for the distinction between intraductal carcinoma of the prostate and cribriform high-grade prostatic intraepithelial neoplasia. Cancer Cell 2010, 34, 478-485.
41. Feng, Z.; Prentice, R.; Srivastava, S. Research issues and strategies for genomic and proteomic biomarker discovery and validation; a statistical perspective. Pharmacogenomics 2004, 5, 709-719.
42. Madu, C.O.; Lu, Y. Novel diagnostic biomarkers for prostate cancer. J. Cancer 2010, 1, 150-177.
43. Verma, M. Pancreatic cancer epidemiology. Technol. Cancer Res. Treat. 2005, 4, 295-301.
44. Verma, M.; Seminara, D.; Arena, F.J.; John, C.; Iwamoto, K.; Hartmuller, V. Genetic and epigenetic biomarkers in cancer: Improving diagnosis, risk assessment, and disease stratification. Mol. Diagn. Ther. 2006, 10, 1-15.
45. Ransohoff, D.F. Rules of evidence for cancer molecular marker discovery and validation. Nat. Rev. Cancer 2004, 4, 309-314.
46. Danila, D.C.; Fleisher, M.; Scher, H.I. Circulating tumor cells as biomarkers in prostate cancer. Clin. Cancer Res. 2011, 17, 3903-3912.
47. Pantel, K.; Brakenhoff, R.H. Dissecting the metastatic cascade. Nat. Rev. Cancer 2004, 4, 448-456.
48. Rosenberg, R.; Gertler, R.; Friederich, J.; Dahm, M.; Phelps, R.; Thorban, S.; Nekarda, H.; Siewert, J.R. Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood. Cytometry 2002, 49, 150-158.
49. Xu, Z.; Bensen, J.T.; Smith, G.J.; Mohler, J.L.; Taylor, J.A. GWAS SNP replication among African American and European American men in the North Carolina-Lusiana prosate cancer project (PCaP). Prostate 2011, 71, 881-891.
50. Ishak, M.B.; Giri, V.N. A systematic review of replication studies of prostate cancer susceptibility genetic variants in high-risk men originally identified from genome-wide association studies. Cancer Epidemiol. Biomarkers Prev. 2011, 20, 1599-1610.
51. Rogler, A.; Rogenhofer, M.; Borchardt, A.; Lunz, J.C.; Knoell, A.; Hofstaedter, F.; Tannapfel, A.; Wieland, W.; Stoehr, R. P53 codon 72 (Arg72Pro) polymorphism and prostate cancer risk: Association between disease onset and proline genotype. Pathobiology 2011, 78, 193-200.
52. Mittal, R.D.; George, G.P.; Mishra, J., Mittal, T.; Kapoor, R. Role of functional polymorphisms of p53 and p73 genes with the risk of prostate cancer in a case-control study from Northern India. Arch. Med. Res. 2011, 42, 122-127.
53. Chang, B.L.; Spangler, E.; Gallagher, S.; Haiman, C.A.; Henderson, B.; Issacs, W.; Benford, M.L.; Kidd, L.R.; Cooney, K.; Storm, S.; et al. Validation of genome-wide prostate cancer associations in men of African descents. Cancer Epidemiol. Biomarkers Prev. 2011, 20, 23-32.
54. Macinnis, R.J.; Antoniou, A.C.; Eeles, R.A.; Severi, G.; Olama, A.A.; McGuffog, L.; Kote-Jarari, Z.; Guy, M.; O'Brien, L.T.; Hall, A.L.; et al. A risk prediction algorithm based on family history and common genetic variants: Application to prostate cancer with potential clinical impact. Genet. Epidemiol. 2011, 35, 549-556.
55. Zheng, S.L.; Hsing, A.W.; Sun, J.; Chu, L.W.; Yu, K.; Li, G.; Gao, Z.; Kim, S.T.; Issacs, W.B.; Shen, M.C.; et al. Association of 17 prostate cancer susceptibility loci with prostate cancer risk in Chinese men. Prostate 2010, 70, 425-432.
56. Kote-Jarai, Z.; Olama, A.A.; Giles, G.G.; Severi, G.; Schleutker, J.; Weischer, M.; Campa, D.; Riboli, E.; Key, T.; Gronberg, H.; et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat. Genet. 2011, 43, 785-793.
57. Parekh, D.J.; Ankerst, D.P. Assessment of 54 biomarkers for biopsy-detectable prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2007, 16, 1966-1972.
58. Parekh, D.J., Ankerst, D.P.; Troyer, D.; Srivastava, S.; Thompson, I.M. Biomarkers for prostate cancer detection. J. Urol. 2007, 178, 2252-2259.
59. You, J.; Cozzi, P.; Walsh, B.; Willcox, M.; Kearsley, J.; Russell, P.; Li, Y. Innovative biomarkers for prostate cancer early diagnosis and progression. Crit. Rev. Oncol. Hematol. 2010, 73, 10-22.
60. Nogueira, L.; Corradi, R.; Eastham, J.A. Other biomarkers for detecting prostate cancer. BJU Int. 2010, 105, 166-169.
61. Dhanasekaran, S.M.; Barrette, T.R. Delineation of prognostic biomarkers in prostate cancer. Nature 2011, 412, 822-826.
62. Goel, M.M; Agarwal, D.; natu, S.M.; Goel, A. Hepsin immunohistochemical expression in prostate cancer in relation to Gleason grade and serum prostate specific antigen. Indian J. Pathol. Microbiol. 2011, 54, 476-481.
63. Wittig-Blaich, S.M.; Kacprzyk, L.A.; Eismann, T.; Bewerunge-Hudler, M.; Kruse, P.; Winkler, E.; Strauss, W.S.; Hibst, R.; Steiner, R.; Schrader, M.; et al. Matrix-dependent regulation of AKT in Hepsin-overexpressing PC3 prostate cancer cells. Neoplasia 2011, 13, 579-589.
64. Talesa, V.N.; Antognelli, C.; DelBuono, C.; Stracci, F.; Serva, M.R.; Cottini, E.l Mearini, E. Diagnostic potential in prostate cancer of a panel of urinary molecular tumor markers. Cancer Biomark. 2009, 5, 241-251.
65. Leman, E.S.; Getzenberg, R.H. Biomarkers for prostate cancer. J. Cell Biochem. 2009, 108, 3-9.
66. Holt, S.K.; Kwon, E.M.; Lin, D.W.; Ostrander, E.A.; Stanford, J.L. Association of hepsin gene variants with prostate cancer risk and prognosis. Prostate 2010, 70, 1012-1019.
67. Perry, A.S.; Watson, R.W.; Lawler, M.; Hollywood, D. The epigenome as a therapeutic target in prostate cancer. Nat. Rev. Urol. 2010, 7, 668-680.
68. Chen, Z.; Wang, L.; Wang, Q.; Li, W. Histone modifications and chromatin organization in prostate cancer. Epigenetics 2010, 2, 551-560.
69. Jeronimo, C.; Bastian, P.J.; Bjartell, A.; Carbone, G.M.; Catto, J.W.; Clark, S.J.; Henrique, R.; Nelson, W.G.; Shariat, S.F. Epigenetics in prostate cancer: Biologic and clinical relevance. Eur. Urol. 2011, 60, 753-766.
70. Syeed, N.; Syed, S.; Hamid, A.; Shah, Z.A.; Afroz, D.; Rasool, R.; Siddiqui, M.A. Promoter methylation profile of GSTP1 and RASS1A in benign hyperplasia and metastatic prostate cancer patients in a Kashmiri population. Mol. Med. Rep. 2010, 3, 883-887.
71. Lee, W.H.; Isaacs, W.B. CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: A new prostate cancer biomarker. Cancer Epidemiol. Biomarkers Prev. 1997, 6, 443-450.
72. Phé, V.; Cussenot, O.; Roupret, M. Methylated genes as potential biomarkers in prostate cancer. BJU Int. 2010, 105, 1364-1370.
73. Chen, Y.; Zaman, M.S.; Deng, G.; Majid, S.; Saini, S.; Liu, J.; Tanaka, Y.; Dahiya, R. MicroRNAs 221/222 and genistein-mediated regulation of ARHI tumor suppressor gene in prostate cancer. Cancer Prev. Res. 2011, 4, 76-86.
74. Majid, S.; Dar, A.A.; Saini, S.; Yamamura, S.; Hirata, H.; Tanaka, Y.; Deng, G.; Dahiya, R. MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer. Cancer 2010, 116, 5637-5649.
75. Zaman, M.S.; Chen, Y.; Deng, G.; Shahryari, V.; Suh, S.O.; Saini, S.; Majid, S.; Khatri, G.; Tanaka, Y.; Dahiya, R. The functional significance of microRNA-145 in prostate cancer. Br. J. Cancer 2010, 103, 256-264.
76. Ambs, S.; Prueitt, R.L.; Yi, M.; Hudson, R.S.; Howe, T.M.; Petrocca, F.; Wallace, T.A.; Liu, C.G.; Volinia, S.; Calin, G.A. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 2008, 68, 6162-6170.
77. Carlsson, J.; Davidsson, S.; Helenius, G.; Karlsson, M.; Lubovac, Z.; Andren, O.; Olsson, B.; Klinga-Levan, K. A miRNA expression signature that separates between normal and malignant prostate tissues. Cancer Cell Int. 2011, 11, 14-16.
78. Ozen, M.; Creighton, C.J.; Ozdemir, M.; Ittmann, M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008, 27, 1788-1793.
79. Porkka, K.P.; Pfeiffer, M.J.; Waltering, K.K.; Vessella, R.L.; Tammela, T.L.; Visakorpi, T. MicroRNA expression profiling in prostate cancer. Cancer Res. 2007, 67, 6130-6135.
80. Khan, A.P.; Poisson, L.M.; Bhat, V.B.; Fermin, D.; Zhao, R.; Kalyana-Sundaram, S.; Michailidis, G.; Nesvizhskii, A.; Omenn, G.S.; et al. Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer. Mol. Cell. Proteomics 2010, 9, 298-312.
81. Varambally, S.; Dhanasekaran, S.M.; Zhou, M.; Barette, T.R.; Kumar-Sinha, C.; Sanda, M.G.; Ghosh, D.; Pienta, K.J.; Sewatt, R.G.; Otte, A.P.; Rubin, M.A.; et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419, 624-629.
82. Vire, E.; Brenner, C.; Deplus, R.; Blanchon, L.; Fraga, M.; Morey, L.; Van Evnde, A.; Bernard, D.; Vanderwinden, J.M.; Bollen, M.; et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006, 439, 871-874.
83. Schatz, P.; Dietrich, D.; Koenig, T.; Burger, M.; Lukas, A.; Fuhrmann, I.; Kristiansen, G.; Stoehr, R.; Schuster, M.; Lesche, R.; et al. Development of a diagnostic microarray assay to assess the risk of prostate cancer based on pITX2 DNA methylation. J. Mol. Diagn. 2010, 12, 345-353.
84. Kwabi-Addo, B.; Ren, C.; Ittmann, M. Dna methylation and aberrant expression of Sprouty 1 in human prostate cancer. Epigenetics 2009, 4, 54-61.
85. Richter, E.; Masuda, K.; Cook, C.; Ehrich, M.; Tadese, A.Y.; Li, H.; Owusu, A. Srivastava, S.; Dobi, A. A role for DNA methylation in regulating the growth suppressor PMEPA1 gene in prostste cancer. Epigenetics 2007, 2, 100-109.
86. Kim, Y.J.; Yoon, H.Y.; Kim, S.K.; Kim, Y.W.; Kim, E.J.; Kim, W.J. EFEMP1 as a novel DNA methylation marker for prostate cancer: Array-based DNA methylation and expression profiling. Clin. Cancer Res. 2011, 17, 4523-4530.
87. Kim, S.J.; Kelly, W.K.; fu, A.; Haines, K.; Hoffman, A.; Zheng, T.; Zhu, Y. Genome-wide methylation analysis identifies involvement of TNF-alpha mediated cancer pathways in prostate cancer. Cancer Lett. 2011, 302, 47-53.
88. Woodson, K.; O'Reilly, K.J.; ward, D.E.; Walter, J.; Hanson, J.; Walk, E.L.; Tangrea, J.A. CD44 and PTGS2 methylation are independent prognostic markers for biochemical recurrence among prostate cancer patients with clinically localized disease. Epigenetics 2006, 1, 183-186.
89. Grizzle, W.E.; Adam, B.; Bigbee, W.L.; Contrads, T.P.; Carroll, C.; Feng, Z.; Izbicka, E.; Jendoubi, M.; Johnsey, D.; Kagan, J.; Leach, R.J.; et al. Serum protein expression profiling for cancer detection: Validation of a SELDI-based approach for prostate cancer. Dis. Markers 2004, 19, 185-195.
90. Robinson, D.; Sandblom, G. PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer. Urology 2008, 72, 903-907.
91. Robinson, D.; Sandblom, G. Prediction of survival of metastatic prostate cancer based on early serial measurements of prostate specific antigen and alkaline phosphatase. J. Urol. 2008, 179, 117-122.
92. Wang, X.; Yin, L.; Rao, P.; Stein, R.; Harsch, K.M.; Lee, Z.; Heston, W.D. Targeted treatment of prostate cancer. J. Cell. Biochem. 2007, 102, 571-579.
93. Duijvesz, D.; Luider, T.; Bangma, C.H.; Jenster, G. Exosomes as biomarker treasure chests for prostate cancer. Eur. Urol. 2011, 59, 823-831.
94. Szendroi, A.; Speer, G.; Tabak, A.; Kosa, J.P.; Nvirady, P.; Romics, I.; Lakatos, P. The role of vitamin D, estrogen, calcium sensing receptor genotypes and serum calcium in the pathogenesis of prostate cancer. Can. J. Urol. 2011, 18, 5710-5716.
95. Choo, C.S.; Mamedov.; Chung, M.; Choo, R.; Kiss, A.; Danjoux, C. Vitamin D insufficiency is common in patients with nonmetastatic prostate cancer. Nutr. Res. 2011, 31, 21-26.
96. Halt, S.K.; Kwon, E.M.; Koopmeiners, J.S.; Lin, D.W.; Feng, Z.; Ostrander, E.A.; Peters, U.; Stanford, J.L. Vitamin D pathway gene variants and prostate cancer prognosis. Prostate 2010, 70, 1448-1460.
97. Edlich, R.; Masson, S.S.; Chase, M.E.; Fisher, A.L.; Gubler, K.; Long, W.B.; Giesy, J.D.; Foley, M.L. Scientific documentation of the relationship of vitamin D deficiency and development of cancer. J. Environ. Pathol. Toxicol. Oncol. 2009, 28, 133-138.
98. Yin, M.; Wei, S.; Wei, Q. Vitamin D receptor genetic polymorphism and prostate cancer risk: A meta analysis of 36 published studies. Int. J. Clin. Exp. Med. 2009, 2, 159-175.
99. Tretli, S.; Harnes, E.; Berg, J.P.; Hestvik, U.E.; Robsahm, T.E. Association between serum 25(OH)D and death from prostate cancer. Br. J. Cancer 2009, 100, 450-454.
100. Barnett, C.M.; Beer, T.M. Prostate cancer and vitamin D: What does the evidence really suggest? Urol. Clin. North Am. 2011, 38, 333-342.
101. Lecornet, E.; Ahmed, H.U.; Moore, C.; Emberton, M. Focal therapy for prostate cancer: A potential strategy to address the problem of overtreatment. Arch. Esp. Urol. 2010, 63, 845-852.
102. Denham, J.W.; Bender, R.; Paradice, W.E. Its time to depolarize the unhelpful PSA-testing debate and put into practice lessons from the two major international screening trials. Med. J. Aust. 2010, 192, 393-396.
103. Mohan, R.; Beydoun, H.; Davis, J.; Lance, R.; Schellhammer, P. Feasibility of using guidelines to choose treatment for prostate cancer. Can. J. Urol. 2010, 17, 4975-4984.
104. Van den Berg, R.C.; van Vugt, H.A.; Korfage, I.J.; Steyerberg, E.W.; Roobol, M.J.; Schroder, F.H.; Essink-Bot, M.L. Disease insight and treatment perception of men on active surveillance for prostate cancer. BJU Int. 2010, 105, 322-328.
105. Kavathia, N.; Jain, A.; Waiston, J.; Beamer, B.A.; Fedarko, N.S. Serum markers of apoptosis decrease with age and cancer stage. Aging 2009, 1, 652-663.
106. Sarrats, A.; Saldova, R.; Commet, J.; O'Donoghue, N.; de Llorens, R.; Rudd, P.M.; Peracaula, R. Glycan characterization of PSA 2-DE isoforms from serum and seminal plasma. OMIC 2010, 14, 465-474.
107. Thomsen, M.K.; Ambroisine, L.; Wynn, S.; Cheah, K.S.; Foster, C.S.; Fisher, G.; Berney, D.M.; Moller, H.; Reuter, V.E.; Scardino, P.; Cuzick, J.; et al. SOX2 elevation in the prostate cancer proliferation and cooperation with PTEN loss to drive tumor formation. Cancer Res. 2009, 70, 979-987.
108. Shamaladevi, N.; Lyn, D.A.; Escudero, D.O.; Lokeshwar, B.L. CXC receptor-1 silencing inhibitis androgen-independent prostate cancer. Cancer Res. 2009, 69, 8265-8274.
109. Ho, E.; Song, Y. Zinc and prostate cancer. Curr. Opin. Clin. Nutr. Metab. Care 2009, 12, 640-645.
110. Yin, M.; Bastacky, S.; Yao, X.D.; Zhang, S.L.; dai, B.; Zhang, H.L.; Shen, Y.J.; Zhu, Y.; Shi, G.H. Prevalence of incidental prostate cancer in the general population: A study of healthy organ donors. J. Urol. 2008. 179, 892-895.
111. Murray, N.P.; Badinez, L.V.; duenas, R.R.; Orellana, N.; Tapia, P. Positive HER-2 protein expression in circulating prostate cells and micro-metastasis, resistant to androgen blockage but not diethylstilbestrol. Indian J. Urol. 2011, 27, 200-207.